Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023Business Wire • 11/13/23
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023Business Wire • 11/10/23
Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive DevelopmentsSeeking Alpha • 11/08/23
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™Business Wire • 11/08/23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsBusiness Wire • 11/02/23
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific OfficerBusiness Wire • 10/30/23
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) ConferenceGlobeNewsWire • 10/12/23
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting® 2023GlobeNewsWire • 10/11/23
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023GlobeNewsWire • 10/05/23
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease ThreatsGlobeNewsWire • 10/03/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 09/27/23
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIVGlobeNewsWire • 09/20/23
Vir Biotech faces steep decline, Bank of America warns amid trial setbacksProactive Investors • 09/08/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/04/23
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/03/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/03/23